Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Indiana University
How would you approach a patient with grade 1/2 pancreatic neuroendocrine tumor after progressing on octreotide?
What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?
Answer from: Medical Oncologist at Community Practice
Tem/cape -- responses are good for pancreatic NET. PRRT Is great but so expensive. I’m finding it so hard to get.
Sign In
or
Register
to read more
6227
Related Questions
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
What factors do you use when considering the addition of celecoxib to adjuvant chemotherapy for patients with stage III colon cancer, given CALGB/SWOG 80702 trial results?
What initial systemic therapy would you offer a patient with metastatic colon cancer with BRAF V600E mutation, MSS, who is not an oxaliplatin candidate?
How would you treat an early-stage dMMR rectal squamous cell carcinoma in an otherwise healthy elderly patient?
Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?
How should immunotherapy be incorporated into the treatment strategy for patients with resectable stage III microsatellite instability–high (MSI-H) or mismatch-repair-deficient (dMMR) extrahepatic cholangiocarcinoma?
Of the two ipilimumab dosing schedules utilized with nivolumab on CheckMate 8HW, do you have a preference in your own practice?
Which GI cancer patients do you use oral contrast in staging CT scans?
How would you manage a frail patient with GCB DLBCL who is unable to complete R-CHOP but has moderate residual disease?